{"id":"W2115961074","doi":"10.1158/1078-0432.ccr-14-1760","title":"The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":92,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Lapatinib; Medicine; Trastuzumab; Breast cancer; Oncology; Clinical trial; Internal medicine; Neoadjuvant therapy; Cancer; Clinical endpoint; Surrogate endpoint; Regimen; Hazard ratio; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07299884,0.001027203,0.003384951,0.001104622,0.0008030549,0.005087847,0.002165096,0.002322328,0.00970612],"category_scores_gemma":[0.09823415,0.0007428448,0.002715383,0.001875956,0.003969358,0.008069767,0.002483662,0.009893812,0.003316069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002316766,"about_ca_system_score_gemma":0.007523085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001801664,"about_ca_topic_score_gemma":0.00281578,"domain_scores_codex":[0.9385394,0.05507864,0.001177219,0.001984763,0.002904126,0.0003158565],"domain_scores_gemma":[0.9049649,0.0723065,0.006016843,0.01139182,0.00370716,0.001612759],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.003011204,0.0004004261,0.006259528,0.009714589,0.003250589,0.0001704114,0.0005043215,0.008115766,0.001970539,0.4724923,0.1563863,0.3377242],"study_design_scores_gemma":[0.0008364529,0.002204111,0.002298758,0.003652541,0.001564597,0.0002436259,0.0002261584,0.01591651,0.0009262902,0.6631396,0.3088102,0.0001812031],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"methods","genre_gemma":"commentary","genre_scores_codex":[0.008684222,0.1600387,0.4209949,0.3549692,0.0191028,0.00189962,0.0042062,0.001160049,0.02894443],"genre_scores_gemma":[0.2530286,0.1262406,0.3543259,0.2168554,0.02137796,0.01029963,0.002504065,0.001056113,0.01431179],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.07299884,"threshold_uncertainty_score":0.3860593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.8736747486636635,"score_gpt":0.7238382028301892,"score_spread":0.1498365458334743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}